Amgen to Build $600 Million Research Center in Thousand Oaks, Creating Hundreds of Jobs

Amgen, a biotech company founded in Thousand Oaks in 1980, is investing $600 million in a new research center for its Thousand Oaks campus. The center will create hundreds of jobs and feature advanced automation and digital capabilities. Construction is expected to begin in Q3 2023. The investment will add to Amgen's existing research and development operations across the US, Canada, and Europe.

Amgen, a biotechnology company based in Thousand Oaks, California, has announced a significant investment of $600 million in the construction of a new Science and Innovation Center at its headquarters. The new facility, scheduled to begin construction in the third quarter of 2025, aims to advance next-generation therapeutics through advanced automation technologies and interdisciplinary collaboration [1][2].

The investment underscores Amgen's commitment to accelerating scientific discovery and innovation. The center will feature state-of-the-art infrastructure designed to enhance research capabilities, with a focus on leveraging automation to streamline processes. This initiative aligns with broader industry trends emphasizing technological integration and collaborative approaches in pharmaceutical development [1][2].

The new center will bring together researchers, engineers, and scientists across disciplines, creating an environment that empowers them with the tools and collaborative space needed to drive scientific excellence and advancements in biotechnology. The facility is expected to create hundreds of jobs during construction and contribute positively to the regional economy [2].

This investment is part of Amgen's broader commitment to U.S. manufacturing and R&D, totaling over $40 billion since 2017, including $5 billion in direct capital expenditures. The new center continues this trend of domestic investment, alongside recent expansions in Ohio and North Carolina [3].

The construction of the new Science and Innovation Center signals management's confidence in Amgen's long-term research pipeline and growth prospects. The facility's focus on cross-disciplinary collaboration and advanced automation directly addresses a critical success factor in modern drug development - the need to accelerate discovery timelines through enhanced scientific collaboration and technology integration [3].

The investment also strategically leverages favorable tax policies from the 2017 Tax Cuts and Jobs Act and the 2025 tax legislation, optimizing Amgen's capital deployment efficiency. This infrastructure investment strengthens Amgen's innovation capabilities while creating jobs and maintaining its competitive edge in the biotech landscape [3].

References:
[1] https://www.geneonline.com/amgen-to-invest-600-million-in-new-science-and-innovation-center-at-thousand-oaks-headquarters/
[2] https://www.powderbulksolids.com/pharmaceuticals-medical-products/amgen-investing-600m-in-new-r-d-center
[3] https://www.stocktitan.net/news/AMGN/amgen-investing-more-than-half-a-billion-dollars-in-new-state-of-the-4ubb6mix6ufq.html